FLUTICASONE FUROATE IN THE TREATMENT OF COPD
The present invention relates to a method of reducing the rate of decline in lung function in a human patient with COPD, wherein the human patient having COPD has a blood eosinophil count of ≥150 cells/μL, and further wherein the method comprises administering to the patient an inhaled pharmaceutical product comprising fluticasone furoate.
1 - 18 . (canceled)
19 . A method of reducing the rate of decline in lung function in a human patient with COPD, wherein the patient having COPD has a blood eosinophil count of ≥150 cells/μL, and further wherein the method comprises administering to the patient an inhaled pharmaceutical product comprising fluticasone furoate.
20 . The method of claim 19 , wherein the inhaled pharmaceutical product comprises a dry powder inhaler, said dry powder inhaler comprising one or more dry powder compositions.
21 . The method of claim 20 , wherein said one or more dry powder-compositions are in unit-dose form.
22 . The method of claim 21 , wherein fluticasone furoate is present in an amount of about 100 mcg/dose.
23 . The method of claim 22 , wherein the inhaled pharmaceutical product further comprises lactose monohydrate.
24 . The method of claim 19 , wherein the inhaled pharmaceutical product further comprises umeclidinium bromide.
25 . The method of claim 24 , wherein the inhaled pharmaceutical product-comprises a dry powder inhaler, wherein said dry powder inhaler comprises one or more dry powder compositions.
26 . The method of claim 25 , wherein said one or more dry powder compositions are present in unit-dose form.
27 . The method of claim 26 , wherein said fluticasone furoate is present in an amount of about 100 mcg/dose, and said umeclidinium bromide is present in an amount of about 62.5 mcg (of the free cation)/dose or 125 mcg (of the free cation)/dose.
28 . The method of claim 26 , wherein said one or more dry powder compositions comprises a first and a second dry powder composition, each in unit dose form, wherein
said first dry powder composition comprises said fluticasone furoate in an amount of about 100 mcg/dose; and;
said second dry powder composition comprises said umeclidinium bromide in an amount of about 62.5 mcg (of the free cation)/dose or 125 mcg (of the free cation)/dose.
29 . The method of claim 28 , wherein
said first dry powder composition comprises said fluticasone furoate and lactose monohydrate; and
said second dry powder composition comprises said umeclidinium bromide and further comprises lactose monohydrate, and magnesium stearate.
30 . The method of claim 29 , wherein said magnesium stearate is present in an amount of 0.6% w/w of said second composition.
31 . The method of claim 29 , wherein said first and second compositions in unit dose form are presented for simultaneous administration.
32 . The method of claim 19 , wherein the inhaled pharmaceutical product further comprises vilanterol trifenatate.
33 . The method of claim 32 , wherein the inhaled pharmaceutical product comprises a dry powder inhaler, said dry powder inhaler comprising one or more dry powder compositions.
34 . The method of claim 33 , wherein said one or more dry powder compositions are present in unit-dose form.
35 . The method of claim 34 , wherein said fluticasone furoate is present in an amount of about 100 mcg/dose and said vilanterol trifenatate is present in an amount of about 25 mcg (of the free base)/dose.
36 . The method of claim 35 , wherein said dry powder inhaler comprises a first and a second dry powder composition,
said first dry powder composition comprising said fluticasone furoate in an amount of about 100 mcg/dose, and;
said second dry powder composition comprising said vilanterol trifenatate in an amount of about 25 mcg (of the free base)/dose.
37 . The method of claim 36 , wherein said first dry powder composition further comprises lactose monohydrate; and said second dry powder composition further comprises lactose monohydrate and magnesium stearate.
38 . The method of claim 36 , wherein said magnesium stearate is present in an amount of 0.6% w/w of the second composition.
39 . The method of claim 36 , wherein said first and second dry powder compositions are in unit dose form and are presented for simultaneous administration.
40 . The method of claim 19 , wherein the inhaled pharmaceutical product further comprises umeclidinium bromide and vilanterol trifenatate.
41 . The method of claim 40 , wherein the inhaled pharmaceutical product comprises a dry powder inhaler, wherein said dry powder inhaler comprising one or more dry powder compositions.
42 . The method of claim 41 , wherein said one or more dry powder compositions are in unit-dose form.
43 . The method of claim 42 , wherein said fluticasone furoate is present in an amount of about 100 mcg/dose, said umeclidinium bromide is in an amount of about 62.5 mcg (of the free cation)/dose or 125 mcg (of the free cation)/dose, and said vilanterol trifenatate is in an amount of about 25 mcg (of the free base)/dose.
44 . The method of claim 43 , wherein the dry powder inhaler comprises a first and a second dry powder composition,
said first dry powder composition comprising said fluticasone furoate in an amount of about 100 mcg/dose, and;
said second dry powder composition comprising said umeclidinium bromide in an amount of about 62.5 mcg (of the free cation)/dose or 125 mcg (of the free cation)/dose and said vilanterol trifenatate in an amount of about 25 mcg (of the free base)/dose.
45 . The method of claim 44 , wherein said first dry powder composition further comprises lactose monohydrate; and said second dry powder composition further comprises lactose monohydrate and magnesium stearate.
46 . The method of claim 45 , wherein said magnesium stearate is present in an amount of 0.6% w/w of the second composition.
47 . The method of claim 45 , wherein said first and second dry powder compositions are in unit dose form and are presented for simultaneous administration.